Cheriana Robinson
Family · Wichita, KSNPI 1952801201
Payments from drug & device makers
Across 135 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$393
- AstraZeneca$278
- Lilly USA, LLC$263
- Novo Nordisk$175
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$146
- Amarin Pharma, Inc.$119
- plus $919 from 21 others
What the payments were for
- Food & beverage$2,294100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $393 |
| AstraZeneca | 15 | $278 |
| Lilly USA, LLC | 20 | $263 |
| Novo Nordisk | 5 | $175 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $146 |
| Amarin Pharma, Inc. | 8 | $119 |
| GSK | 6 | $114 |
| Bayer | 7 | $108 |
| Amgen | 6 | $96 |
| Merck | 6 | $92 |
| Pfizer | 4 | $68 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Astellas Pharma US Inc | 2 | $42 |
| Abbott | 2 | $41 |
| Johnson & Johnson | 3 | $40 |
| Cranial Technologies, Inc | 2 | $39 |
| Boehringer Ingelheim | 2 | $33 |
| Ironwood Pharmaceuticals, Inc | 2 | $30 |
| Ardelyx, Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Medtronic | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$106
How this compares
$2,294 in reported general payments places this provider in the 85th percentile of 1,579 family providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 14 | $17,150 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,191 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $757 |
| Methocarbamol | 12 | $629 |
| Atorvastatin Calcium | 65 | $575 |
| Potassium Chloride | 14 | $456 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $408 |
| Propranolol Hcl | 12 | $402 |
| Lisinopril | 38 | $329 |
| Gabapentin | 22 | $322 |
| Simvastatin | 41 | $140 |
| Amlodipine Besylate | 34 | $102 |
| Tamsulosin Hcl | 23 | $93 |
| Losartan Potassium | 29 | $87 |
| Allopurinol | 15 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $175 | $17,15014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,579 family providers in Kansas.
Other family in Wichita
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Mary GonzalesWichita$87K
- Mary GarciaWichita$24K
- Jennifer NeelWichita$15K
- Amanda AstWichita$9K
- Jennifer MartinWichita$8K
- Lauren CoteWichita$7K
- Mimi TranWichita$6K
- Kara NabboutWichita$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.